Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Kate Shaw reflects on Innovative Trials’ first US office openings

On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening

Innovative Trials

- PMLiVE

Reimagining strategy development for a hybrid workforce

By Janice MacLennan

CALM_Invisible_Opponent_KV_Press_Release

Declan Rice features in new campaign for suicide prevention charity Campaign Against Living Miserably

New CALM campaign fronted by West Ham and England footballer aims to tackle loneliness

SEVEN STONES COLLECTIVE

regeneron headquarters

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

A phase 3 trial demonstrated a 31% reduction in the risk of death compared to chemotherapy

- PMLiVE

AbbVie’s Skyrizi receives EC approval for active Crohn’s disease

The approval makes Skyrizi the first specific IL-23 inhibitor as a Crohn's treatment in the EU

- PMLiVE

Merck’s Keytruda meets primary endpoint in phase 3 gastric cancer trial

Gastric cancer is the fourth leading cause of cancer death worldwide

Can Cinderella save us?

UK government launches consultation on silent AMR pandemic

The consultation will call upon the latest data from experts on antimicrobial resistance

- PMLiVE

FDA approves first gene therapy for adults with haemophilia B

CSL’s Hemgenix allowed patients to produce mean factor IX activity of 39% at six months

- PMLiVE

Porterhouse Medical US celebrates 5 years of working in harmony with our client partners

Globally acclaimed healthcare communications and medical insights network, Porterhouse Medical Group, is delighted to announce that our US-based team is celebrating its fifth anniversary this month. Porterhouse Medical US was...

Porterhouse Medical Group

- PMLiVE

How telemonitoring can revolutionise the way we treat patients

By Tom York

- PMLiVE

Merck to acquire Imago BioSciences in deal worth $1.35bn

The agreement includes lead candidate, bomedemstat, for myeloproliferative neoplasms

- PMLiVE

Cancer Research Horizons and Newcastle University extend alliance with Astex

The agreement will extend the current alliance between the three parties by a further five years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links